# Moving towards Personalized Medicine--The Broad Use of Aptamers for Targeted Theranostic
## 2 Cancer Therapeutics
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline \multirow{2}{*}{**Cancer Site**} & \multirow{2}{*}{**Aptamer**} & \multirow{2}{*}{**Target**} & \multicolumn{3}{c}{**Application**} & \multirow{2}{*}{**References**} \\ \cline{5-5} \cline{5-5}  & & & **Diagnostic** & **Therapy** & **Theranostic** \\ \hline \multirow{5}{*}{Prostate} & Apt63 & APT5B & X & & [34] \\  & A9g & PSMA & X & & [35] \\  & PSMA-specific RNA aptamer & PSMA & X & & [36] \\  & AGR0100 & Nucleolin & X (PCS I) & & [37] \\  & CG3 & PCA3 & & & [38] \\  & AS1411 & Nucleolin & X & & [39] \\  & shRNA/PEI-PEG-APT/DOX & \multirow{2}{*}{PSMA positive cells} & & X & [40] \\  & conjugates & & & & [41] \\ \hline Glioblastoma & 40L & CD133 & X & & [41] \\ \hline Oral & Anti-HPSE1 & Heparanase & X & & [42] \\ \hline Cervical & A2 & E6 and E7 oncogenes & X & & [43] \\ \hline Bladder & alncRNA & TFs & X & & [44] \\ \hline Gastric & Trimeric & ErbB-2/HER2 & X & & [45] \\ \hline \multirow{2}{*}{Leukemia} & AS1411 & Nucleolin & & X & [46] \\  & ap-8-arrestin2 & \(\beta\)-arrestin2 & & X & [47] \\  & ssRNA MLL-1 & MLL-1 & X & & [48] \\ \hline \multirow{2}{*}{Indkins lymphoma} & \multirow{2}{*}{CD-RNA aptamer + HAuNS} & CD30 & X & & [49] \\ \hline Myeloma & NOX-A12 & CXCL12 & & X & [17] \\ \hline Skin & F3B & MMP-9 & X & & [50] \\ \hline \multirow{5}{*}{Pancreas} & E07 & EGFR & & X & [51] \\  & P19 & C/EBP\(\star\) + saRNA & & & [52] \\  & P1 & & hf7R protein & & & [52] \\  & TfR aptamer-C/EBP\(\star\)-saRNA & & & & [53] \\  & conjugates & & & & [53] \\  & XQ-2d-His-SHZ CM-(Arg)9 & \multirow{2}{*}{PDAC stroma} & & X & [54] \\  & conjugate & & & & [55;56] \\  & SQ-2 & ALPP L-2 & & & X & [57] \\  & Apt1 & CD24/44/133 and EpCAM & & & [57] \\  & Ap146 & & & & [58] \\  & X-aptamer & Thy-1 & & & [59] \\  & Aptacy & TfR & & & [60] \\  & NOX-E36 & CCL2 & & & [61] \\  & Cyclophilin B & Secretome & X & & [62] \\  & P12 FR2 & PAUF & & X & [63] \\  & NOX-A12 & CXCL12 & & & [63] \\ \hline \multirow{5}{*}{Non-specific} & 4+1 BB & TNPSP9 & X & & [64] \\  & OX40 & TNFSF4 & & & [65] \\  & GL2.1T & Axl domain & & & [66] \\  & Ap-biRNA & - & & & [67] \\  & CAR-like multivalent aptamer & & & [68] \\  & Bi-functional aptamers & Opsonin C30/iC3b & X & & [69] \\  & AS1411 & and cyclic peptide & Alpha-v beta 3 (avp83) & & [70] \\  & RGD & & & [71] \\  & H02 & integrin & x5B1 & & [72] \\  & Dox-incorporated multivalent & Multidrug resistance cancer & & [72] \\  & aptamer-siRNA conjugates & & & [73;74] \\  & Ap52 & MAGE-A3 & X & [73;74] \\ \hline \hline \end{tabular} Abbreviations: HeLa-3: HER-positive aptamer 2-3; PNDA-3: periostin Aptamer; apMN2F/apMN3R: aptamer against Mitogen-activated protein kinase-interacting kinases 2F and 3R; ex-50.T: aptamer targeting breast cancer exosomes; AS1411: ssDNA aptamer for nucleolin; YJ-1: alexa Fluor 488-labeled YJ-1 aptamer; apPDCF-BB: platelet-derived growth factor-BB aptamer; apPD-1: aptamer for PDI; protein of CD28 family; NOX-A12: L-stereosensor RNA aptamer that binds and neutralizes CXCL12; apPD-LD1: aptamer for PD-LD1; protein of CD28 family; AP-74 N-545: galectin-specific DNA aptamer; TBA353 and TBA355: aptamers that form G-quadruplex structures (no anticoagulant); RA16: aptamer that detects NCI-H460 cells; CL-4 RNVF616: aptamer that inhibit the proliferation of U87 MG GGN cells by targeting EGFR; SW4 and SW-40: aptamer for RCC 786-O- cells recognition; Apt63: aptamer that binds to the beta subunit of FIFO ATP synthase; A9g and PSMA: aptamer for prostatic specific membrane antigen; AGCR0100: same as the AS1411 aptamer; CGS: aptamer that binds to PCA3 protein; 40L and A40s: 2’-’fluocytrimidine RNA aptamers; Anti-HPSE1: aptamer for HPSE-1; A2: antagomic aptamer for \(\beta\)-arrestin2; ssRNA MLL-1; alncRNA: aptamers that bind to \(\beta\)-catenin and NF-xB; ap-arrestin2: aptamer for \(\beta\)-arrestin2; ssRNA MLL-1; aptamer used for mixed-lineage leukemia 1; F3B: aptamer that recognizes MMP-9; +1 BB: aptemtem that stimulates CD8+ cells; OX40: aptamer that recognizes the tumor necrosis factor receptor superfamily; GL21:F: extracellular domain of Axl at high affinity binding aptamer; H02: aptamer that differentiate glioblastoma cell lines; HER2: Human Epidermal growth factor Receptor-type 2; MNKI: MAPK-interacting kinases 1; CEA: Carcinomyproxion antigen; PDCF-BB: platelet-derived growth factor-BB; PD-1: programmed cell death 1; CXCL12: chemokine C-X-C motif ligand 12; IFN-v: Interferon-gamma; TBA: thrombin binding aptamer; NSCLC: non-small cell lung cancer;  
\end{table}